



APPLICATION FOR STEM CELL OVERSIGHT COMMITTEE REVIEW

INFORMATION SHEET (do not submit this page with completed application form)

Researchers should consult the *Guidelines for Human Pluripotent Stem Cell Research* ("the Guidelines") and Frequently Asked Questions posted on the CIHR website http://www.cihr-irsc.gc.ca/e/15255.html to determine whether or not the research requires review by the Stem Cell Oversight Committee (SCOC). Any questions can be directed to stemcell@cihr-irsc.gc.ca.

IF YOUR APPLICATION:		COMPLETE SECTIONS
•	Will use existing SCOC-approved human embryonic stem cells	A,D
•	Includes experiments involving the engraftment of induced human pluripotent stem cells into human and/or non-human animals	A,D
•	Is for Trainee or student funding	A,B,D
•	Is to derive human pluripotent stem cells from human embryos, fetal tissue, or amniotic fluid	A,C,D
•	Will use existing human pluripotent stem cells that have been derived from human embryos, fetal tissue, or amniotic fluid, and have not yet been approved by SCOC	A,C,D

Additional information may be requested from the researcher if SCOC has concerns that are not addressed in the documentation provided.

Governing Council has delegated its authority to approve research using existing SCOC-approved human embryonic stem cell (hESC) lines and/or human induced pluripotent stem (iPS) cells to SCOC, unless the research involves the engraftment of those cells into humans. SCOC will respond to research proposals within its delegated authority within 30 business days of receipt of a complete application.

Governing Council's approval is required on all other types of research proposals (e.g., research involving the derivation of hESC from human embryos, the use of hESC lines not yet approved by SCOC, and/or the engraftment of human pluripotent stem cells into human beings).

Please send completed form to:

Stem Cell Oversight Committee Canadian Institutes of Health Research 160 Elgin St., 9th Floor Address Locator 4809A Ottawa, Ontario K1A 0W9

Date Received by CIHR:

APPLICATION FOR STEM CELL OVERSIGHT COMMITTEE REVIEW

A. GENERAL INFORMATION

APPLICATION DETAILS:					
Nominated Principal Applicant:					
M ''' 11 (5: 14 !'					
Mailing address of Principal Applicar	nt:				
E-mail address of Principal Applicant	t				
E-mail address of Finicipal Applicant	•				
All Other Applicants:					
Title of application for funding:					
Funding Agency:	Funding competition:	Application Number:			
runding Agency.	Tunung competition.	Application Number:			
Application status:	(as by finding considering National States				
	'es, by funding organization ☐ Not peer reviewed ☐				
Approved for funding: Yes, date of approval:	////////(dd/mm/yyyy)				
Submitted to funding opport					
☐ Pilot project using existing g					
Other (please describe):	, 				
OVERVIEW:					
	use of human induced pluripotent stem cells?				
☐ Yes	• •				
□ No					
If 'Yes':					
 and the answers to 2, 3 ar 	nd 4 are all 'No', then the research does not require SC	OC review			
and the answers to 2 and	4 are 'No' and the answer to 3 is 'Yes', but limited to te	ratoma formation, then the			
	research does not require SCOC review. Do not submit this form. However, you must inform SCOC in				
writing (at address above) that human pluripotent stem cells will be used for teratoma formation only and					
	ne animals will not be used for reproductive purposes.	·			
2. Does this research propose the use of human embryonic stem cells?					
Yes (see below)					
□No					
If 'Yes':					
Please list all lines that \(\)	will be used:				
 If any of these lines have 	e not been approved by SCOC, please complete sec	tion C			
	engrafted with human pluripotent stem cells or cell	s derived from human			
pluripotent stem cells in this pro	oject?				
Yes (see below)					
∐ No					
	If 'Yes':				
	iments are not described in detail in the application	for funding, please			
provide a description of these experiments					
 Will any non-human animals engrafted with human pluripotent stem cells or cells derived from 					
human pluripotent stem cells in the course of this research be used for reproductive purposes?					
□ Yes					
No	ng human plurinotont stom call lines into human au	phinate?			
 Does the research involve grafting human pluripotent stem cell lines into human subjects? ☐ Yes (see below) 					
☐ No					
If 'Yes':					
Append copies of consent and information forms to be used					
 Ensure that the proposal describes evidence from preclinical models for safety and efficacy, and that the research is carried out in well-designed clinical trials. You may append additional 					
information if needed to provide more details than contained in the application.					
information if needed to provide more details than contained in the application.					

OVEDVIEW.
OVERVIEW:
5. Describe the potential benefits of this research:
APPENDICES:
Description of how each of the human pluripotent stem cell lines will be used. Please list each experiment that
involves the use of human pluripotent stem cells and briefly (5-10 lines) describe how the cells will be used in each.
This will ensure that SCOC has a clear understanding of which experiments proposed in the application for funding
involve the use of human pluripotent stem cells.
One copy of the original application for funding. Please include the budget, the list of patents held by the
principal applicant, and the list of the funds requested and the funds held by all applicants.
Copies of any contracts relevant to this application, and any relevant budgetary information. Failure to append
relevant contracts may delay grant approval (please see Section 8.4.2 of the Guidelines): Copies of contracts
between researchers, institutions and industry sponsors and any relevant budgetary information must be provided to
the Stem Cell Oversight Committee and the local REB, to examine and evaluate any potential or actual conflict of
interest and to ensure the right to publish freely after a modest interval. Should any potential conflicts of interest arise
following approval of an application, the Stem Cell Oversight Committee must be advised.
Please list all contracts that are appended:
Flease list all contracts that are appended.
☐ There are no relevant contracts
Description of any financial interest you may have in the outcome of the research described in this
application (please see Section 8.4.1 of the Guidelines): In some instances, disclosure may not be a sufficient
response to concerns about actual, perceived or potential conflicts of interest and researchers and/or their institutions
may be asked by SCOC to remedy any possible distortion of proper procedures attributable to such conflicts. Should
any potential conflicts of interest arise following approval of an application, the Stem Cell Oversight Committee should
be advised.
Please explain the commercial plan in a few short sentences:
Lhave no financial interact in the autoeme of the received described in this application
☐ I have no financial interest in the outcome of the research described in this application
ATTESTATIONS:
i) An amended application will be submitted to SCOC for review and approval if:
a. any changes in direction of the research involving human pluripotent stem cells are planned, before such
work commences
b. a Trainee receives separate funding for related research.
☐ Yes
│
ii) SCOC will be provided with written notification should the use of additional SCOC-approved stem cell lines
not described in the original research application be planned (this notification would include the title of the
original application, the name of the PI and indicate which cell lines would be used).
☐ Yes
No
iii) I understand my research institution's conflict of interest policy and will comply with that policy.
, , <u> </u>
Yes
□ No

B. APPLICATIONS FOR TRAINEE OR STUDE	NT	
RESEACH SUPPORTED BY TRAINEE OR STU		
Is this application for Trainee or student funding	wholly subsidiary to a SCOC-approved pr	roject?
Yes (see "Attestations" below)		
□ No		
ATTESTATIONS:	- H	
Yes, the Trainee or student proposal is wh	only subsidiary to the SCOC-approved	project:
Title:		
Led By:		
Funded By:		
Date approved by SCOC:		
Supervisor's signature:		
oupor ricor o dignataro.		
C. APPLICATIONS TO:		
• DERIVE HUMAN PLURIPOTENT STEM C	ELLS FROM HUMAN EMBRYOS, FETA	AL TISSUE, OR AMNIOTIC
FLUID; AND/OR		/
USE EXISTING HUMAN PLURIPOTENT S FETAL TISSUE, OR AMNIOTIC FLUID, W		
DESCRIPTIONS:		
If this application is being submitted to use h	uman embryos to derive human embry	yonic stem cells, please
describe the need for human embryos:		
☐This is not an application to derive human	ombryonic stom colls	
APPENDICES:	embryonic stem ceils	
Copies of consent and information forms	used	
a) unsigned research consent (see section 8.3.2		
b) unsigned embryo donor or research subject co		
c) information forms	,	
SCOC will review these documents to ensure that		s (see 8.1, 8.3) and the Final
Report of the ad hoc Working Group on Stem Ce		
Attestation(s) that the embryos have been such purposes	created for reproductive purposes and	d are no longer required for
Attestation(s) that neither the ova nor the		reated, nor the embryos
themselves, have been obtained through o	commercial transactions	
Attestation(s) that the researchers did not		
treatment team to generate more embryos Attestation(s) that the embryos have not/w		
ATTESTATIONS:	mi not be grown in vitro for more than	т чауэ
Any human embryonic stem cell lines genera	ted under the auspices of federal fund	ling agencies (CIHR, NSERC.
SSHRC) will be listed with the registry and ma		
recovery charges.	•	
☐ Yes		
☐ Not applicable		
D: SIGNATURES		
I certify that all information provided above is	correct to the best of my knowledge.	
- 125 my stat at mismation provided above is	contact to the book of my knowledge.	
Nome	Ciamater	D-4-
Name	Signature	Date
Name	Signature	Date
Tiumo	O.g.,	Duto
Name	Signature	Date
Name	Signature	Date
Name	Signature	Date